Rehn D, Hennings G, Nocker W, Diebschlag W
Zyma GmbH, Technischen Universität München, FRG.
Eur J Clin Pharmacol. 1991;40(6):625-7. doi: 10.1007/BF00279983.
O-(beta-hydroxyethyl)-rutosides (HR) is used for the treatment of disorders of the venous and microcirculatory systems. In order to evaluate the time course of its activity, the effect of HR on a provocation model of orthostatic oedema in healthy volunteers was used. After a 2 week placebo run-in period, 16 healthy volunteers were randomized to HR (2 tablets of 500 mg/day) of placebo for a further 3 weeks, in a double-blind parallel design. Oedema was provoked by standing motionless for 1 h, with measurement of leg volume before and afterwards. The procedure was undertaken at entry to the study and then weekly during the entire 5 week period. There were no significant differences in the extent of oedema produced by the orthostatic challenge during the 2 week run-in period or in the subjects who continued on placebo (approximately 90 arbitrary units i.e. approximately 48 ml). During the 3 week treatment with HR, however, there was a progressive reduction (-1.1, -5.9, and -7.6 arbitrary units after 1, 2, and 3 weeks, respectively) in the volume of induced oedema, which was significant after 2 and 3 weeks of treatment compared to the placebo group.
羟乙基芦丁(HR)用于治疗静脉和微循环系统紊乱。为了评估其活性的时间进程,采用了HR对健康志愿者体位性水肿激发模型的影响。经过2周的安慰剂导入期后,16名健康志愿者被随机分为HR组(2片,500mg/天)或安慰剂组,采用双盲平行设计,再进行3周的治疗。通过静立1小时诱发水肿,分别测量前后腿部体积。该操作在研究开始时进行,然后在整个5周期间每周进行一次。在2周的导入期或继续服用安慰剂的受试者中,体位性激发引起的水肿程度没有显著差异(约90个任意单位,即约48毫升)。然而,在HR治疗的3周期间,诱发水肿的体积逐渐减少(1周、2周和3周后分别为-1.1、-5.9和-7.6个任意单位),与安慰剂组相比,治疗2周和3周后差异显著。